SAMD12 and benign adult familial myoclonic epilepsy: This panel offers a promising proof-of-concept molecular tool that, with further validation, may serve as a clinically valuable method for the molecular diagnosis of FAME1 and the genetic diagnosis of other FAME subtypes.